Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02567409 · ClinicalTrials.gov registry record · Phase 2
Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer
A Phase 2 study of Metastatic Bladder Urothelial Carcinoma and Metastatic Ureter Urothelial Carcinoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
- 20
- Study locations
NCT02567409 is a Phase 2 study of Metastatic Bladder Urothelial Carcinoma and Metastatic Ureter Urothelial Carcinoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 87 participants, below the 119-participant average among 13 other Metastatic Bladder Urothelial Carcinoma trials with a reported enrollment target (27% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT02567409, a Phase 2 study of Metastatic Bladder Urothelial Carcinoma and Metastatic Ureter Urothelial Carcinoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial studies how well cisplatin and gemcitabine hydrochloride with or without berzosertib works in treating patients with urothelial cancer that has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as cisplatin and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Berzosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known if cisplatin and gemcitabine hydrochloride work better alone or with berzosertib in treating patients with urothelial cancer.
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Gemcitabine Hydrochloride
- DRUG Berzosertib
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center - Duarte
- Los Angeles General Medical Center - Los Angeles
- USC / Norris Comprehensive Cancer Center - Los Angeles
- USC Norris Oncology/Hematology-Newport Beach - Newport Beach
- Stanford Cancer Institute Palo Alto - Palo Alto
- Keck Medical Center of USC Pasadena - Pasadena
- University of California Davis Comprehensive Cancer Center - Sacramento
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Brigham and Women's Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
Arizona
- Mayo Clinic Hospital in Arizona - Phoenix
- Mayo Clinic in Arizona - Scottsdale
Kansas
- University of Kansas Clinical Research Center - Fairway
- University of Kansas Hospital-Westwood Cancer Center - Westwood
Colorado
- UCHealth University of Colorado Hospital - Aurora
Florida
- Mayo Clinic in Florida - Jacksonville
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
Kentucky
- University of Kentucky/Markey Cancer Center - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2017-01-31 |
| Est. Completion | 2023-04-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02567409
The ClinicalTrials.gov registry entry for NCT02567409 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 119-participant average among 13 other Metastatic Bladder Urothelial Carcinoma trials with a reported enrollment target (27% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Metastatic Bladder Urothelial Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Cisplatin is the first listed.
NCT02567409 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Massachusetts, Arizona.
Frequently Asked Questions
What is clinical trial NCT02567409 about?
NCT02567409 is a clinical study titled "Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer". This phase II trial studies how well cisplatin and gemcitabine hydrochloride with or without berzosertib works in treating patients with urothelial cancer that has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as cisplatin and gemcitabine hydrochloride, work in di...
What is the current status of trial NCT02567409?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2017-01-31. Estimated completion is 2023-04-25.
What conditions does trial NCT02567409 study?
This clinical trial studies the following conditions: Metastatic Bladder Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma AJCC v7, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma.
What interventions are being tested in trial NCT02567409?
The interventions under investigation include: Cisplatin (DRUG), Gemcitabine Hydrochloride (DRUG), Berzosertib (DRUG).
Who is sponsoring clinical trial NCT02567409?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02567409 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Bladder Urothelial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors
RECRUITING · Phase 2
-
Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers
RECRUITING · Phase 2
-
ARID1A and/or KDM6A Mutation and CXCL13 Expression
ACTIVE NOT RECRUITING · Phase 2
-
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
COMPLETED · Phase 2
Explore more on PlainTrial
Metastatic Bladder Urothelial Carcinoma
All registered trials for this condition
Metastatic Ureter Urothelial Carcinoma
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.